Roche formed a strategic collaboration with the drug discovery company Warp Drive Bio to develop new classes of antibiotics.
Here are three things to know.
1. Warp Drive will use its Genome Mining Platform to identify and develop antibiotic classes for drug-resistant, Gram-negative pathogens.
2. Roche has an option for exclusive worldwide license to develop and commercialize some antibiotic classes that arise from the collaboration.
3. Warp Drive will receive up to $87 million in an upfront payment, option fees and milestone payments for preclinical events. The company is also eligible to receive up to $300 million in payments relating to specific clinical, regulatory and sales milestones.
"We are committed to bringing urgently needed novel antibiotic medicines to patients, and we are delighted to be collaborating with Roche in that goal," said Laurence Reid, PhD, CEO of Warp Drive Bio. "Antimicrobial resistance is an extraordinary threat to global human health, and Warp Drive's unique platform allows us to access a vast reservoir of uncharacterized natural products from which to identify novel antibiotics."
More articles on supply chain:
J&J's psoriasis drug OK'd for teens
FDA approves robotically-assisted surgical device
Baxter expects temporary shortage of small saline IV bags